UNIVERSITY OF ALABAMA AT BIRMINGHAM

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1969-01-01

Employees: 2K

Market Cap: -

Website: http://www.uab.edu

Clinical Trials

Vascular Reparative Mechanism in Diabetes

Active, not recruiting

Conditions: Diabetic Retinopathy

Interventions: Other: Diabetic Patients
Other: Healthy Controls

First Posted Date: 2014-04-22

Last Posted Date: 2024-10-30

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 78

Registration Number: NCT02119689

Locations: 🇺🇸
University of Alabama, Birmingham, Alabama, United States

Low Dose Naltrexone (LDN) Immune Monitoring

Not Applicable

Completed

Conditions: Fibromyalgia

Interventions: Drug: Low Dose Naltrexone

First Posted Date: 2014-04-08

Last Posted Date: 2017-04-11

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 9

Registration Number: NCT02107014

Locations: 🇺🇸
Stanford University School of Medicine, Palo Alto, California, United States

Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults

Phase 2

Completed

Conditions: Neurofibromatosis
NF1
Plexiform Neurofibromas

Interventions: Drug: Cabozantinib

First Posted Date: 2014-04-02

Last Posted Date: 2023-05-24

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 45

Registration Number: NCT02101736

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸
Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

and more 9 locations

Evaluating Expectancy Effects in Weight Loss Measurement

Completed

Conditions: Accuracy of Clinic-based Weight Measurements

Interventions: Other: clinic-based weight measurements

First Posted Date: 2014-04-02

Last Posted Date: 2019-09-17

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 59

Registration Number: NCT02101658

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1

Phase 2

Completed

Conditions: Neurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN

Interventions: Drug: PD-0325901

First Posted Date: 2014-03-26

Last Posted Date: 2019-01-10

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 19

Registration Number: NCT02096471

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Indiana Unversity, Indianapolis, Indiana, United States

and more 8 locations

Comparison of Weight Management Programs Delivered in Large Versus Small Groups

Not Applicable

Completed

Conditions: Obesity

Interventions: Behavioral: lifestyle intervention for obesity

First Posted Date: 2014-03-17

Last Posted Date: 2024-01-11

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 66

Registration Number: NCT02088749

Locations: 🇺🇸
Florida State University, Tallahassee, Florida, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

EUS-FNA With and Without Suction

Not Applicable

Completed

Conditions: Solid Pancreatic Mass Lesions

Interventions: Procedure: Suction

First Posted Date: 2014-02-27

Last Posted Date: 2014-11-10

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 72

Registration Number: NCT02072915

Locations: 🇺🇸
UAB, Birmingham, Alabama, United States

Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis

Phase 2

Completed

Conditions: Severe Aplastic Anemia
Leukemia
Myelodysplastic Syndrome
Myelofibrosis
Allogeneic Transplant
Lymphoma

Interventions: Drug: Cyclophosphamide

First Posted Date: 2014-02-17

Last Posted Date: 2022-09-30

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 39

Registration Number: NCT02065154

Locations: 🇺🇸
UAB Bone Marrow Transplantation and Cellular Therapy Program, Birmingham, Alabama, United States

Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma

Phase 1

Active, not recruiting

Conditions: Recurrent Glioblastoma Multiforme
Progressive Glioblastoma Multiforme
Anaplastic Astrocytoma or Gliosarcoma

Interventions: Biological: M032 (NSC 733972)

First Posted Date: 2014-02-14

Last Posted Date: 2024-10-08

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 29

Registration Number: NCT02062827

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa

Completed

Conditions: Antiretroviral Therapy
Alcohol Use Disorder
Hepatitis B Virus
HIV
Africa
Liver Fibrosis

Interventions: Other: Standard of care

First Posted Date: 2014-02-11

Last Posted Date: 2021-11-12

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 897

Registration Number: NCT02060162

Locations: 🇿🇲
Centre for Infectious Disease Research in Zambia, Lusaka, Zambia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy